IMV Inc IMVIF

Hurdle rate bladder and MSS High are super good

[Biotech010]

Wells Fargo analyst Nick Abbott put a $14 PT on the stock. You want to know why....????

The basket trial results from the KEYTRUDA combination data in MSS-high solid tumors and  bladder cancer are impressive. The so called hurdle rate... when to go / stop a trial... wasn't published in the press release. But this info was in the Wells Fargo report.

And the results were super good and way beyond what KEYTRUDA achieved in monotherapy. WIth this data coming up in Q4 2021... we should really see upward momentum for the stock.

Andrew en Jeremy are doing great work communicating and telling the IMV story.

 

[alphaseeking001]

Anyone have access to the Wells Fargo note?  If so, could they post it up here? Thanks quote=Biotech010] Wells Fargo analyst Nick Abbott put a $14 PT on the stock. You want to know why....???? The basket trial results from the KEYTRUDA combination data in MSS-high solid tumors and  bladder cancer are impressive. The so called hurdle rate... when to go / stop a trial... wasn&

[Hideaway]

Alpha,I would also appreciate more details from the WF report.Not sure I understand how this WF analyst could get access to this information as it appears to be material matters that the Company would have to officially release.It is certainly news that should propel the SP northward if subistanted.One would think that such a leak would have an immediate and positive effect on the shares but this

[alphaseeking001]

Agreed Hideaway.  My feelings exactly.  That's why I'd like to see the report.  I bought back a bit more the other day.  I feel that any good news could bump the stock a bit.  Even an announcement of a  new replacement CEO... providing they have solid experience.  I'm a bit surprised they haven't hired someone yet.  I'd rather they find

[Biotech010]

8 weeks to deliver some big PR's. I really look forward to the basket trial. In the latest presentation it says Bladder and MSI "Promising preliminary results"  I spoke to some European investors and they are buying on the dip. The next 6-9 months should be life changing for IMV. I really urge investors to contact the company if they have any questions.  Despite the

[Lambom]

Why contact the company? Marc's responses are dull , generic , does not answer questions lol heck he does not even answer his phones. At this point its just a roll of the dice. 

[Biotech010]

try Pierre, always quick and he does has something to say;)